Older Americans who take daily multivitamins expecting protection against cancer or heart disease are spending money on products that two of the largest randomized trials ever conducted found do not deliver those benefits. The COSMOS trial, which enrolled 21,442 U.S. adults, and the earlier Physicians’ Health Study II both failed to show that routine multivitamin use meaningfully reduced major cardiovascular events in generally healthy seniors. At the same time, federal health agencies warn that some of those same supplements can interfere with prescription medications, creating risks that many older adults and their doctors never discuss.
Why the gap between supplement marketing and trial data matters right now
The disconnect between what supplement labels imply and what clinical evidence supports has direct consequences for people over 60 who take multiple prescription drugs. The National Institute on Aging states plainly that dietary supplements can cause unwanted side effects, including unsafe interactions with prescription drugs. Because supplements are regulated differently than prescription medications, they reach store shelves without the same pre-market safety testing the FDA requires for pharmaceuticals. That regulatory gap means a senior taking a blood thinner, a statin, or a diabetes drug may unknowingly add a supplement that changes how those medicines work in the body.
One practical question follows from this evidence: could pharmacist-led medication reviews that explicitly screen for supplement use reduce drug-interaction incidents? The logic is straightforward. Pharmacists already review prescription lists for conflicts. Adding a structured supplement check during those reviews would surface hidden risks before they cause harm. If tested in a controlled study, seniors receiving such screenings could show a measurable drop in interaction-related adverse events within six months compared with those getting standard care. No large trial has yet validated this specific intervention at scale, but the clinical rationale is strong enough that health systems looking to reduce preventable harm in older populations should be tracking this approach closely.
What the COSMOS and Physicians’ Health Study II actually found
The COcoa Supplement and Multivitamin Outcomes Study, known as COSMOS, remains one of the most rigorous tests of whether a daily multivitamin prevents cancer or cardiovascular disease in older adults. The randomized trial of COSMOS enrolled 21,442 U.S. adults, including women aged 65 and older and men aged 60 and older. Participants were assigned to take either a daily multivitamin or a placebo, alongside a separate cocoa extract arm. The trial was designed to detect even modest reductions in cancer incidence and major cardiovascular events. Its results did not support the widespread belief that multivitamins serve as a reliable shield against those conditions in well-nourished older populations.
The Physicians’ Health Study II reinforced that finding from a different angle. That randomized controlled trial focused on cardiovascular disease prevention in men and likewise found no significant reduction in major cardiovascular events among multivitamin users. Taken together, these two large-scale trials represent thousands of person-years of follow-up and consistent null results for the most commonly marketed benefits of daily multivitamins. The evidence does not suggest that multivitamins are harmful on their own for most healthy adults, but it does challenge the assumption that they provide a meaningful preventive benefit against the diseases older Americans fear most.
The interaction risk, by contrast, is well documented. The National Center for Complementary and Integrative Health has compiled clinical evidence showing that common herbal supplements can alter the metabolism of prescription drugs or raise toxicity risks. St. John’s wort, for example, is known to reduce the effectiveness of certain antidepressants, birth control pills, and blood thinners. Garlic supplements in high doses can amplify the effects of anticoagulants. The NCCIH’s clinical digest on herb–drug interactions notes that high-quality clinical interaction trials remain limited, but established concerns about interaction potential, direct toxicities, and contamination are serious enough to warrant caution. The FDA has separately flagged tainted products marketed as dietary supplements that contain hidden drug ingredients or analogs, adding another layer of risk for consumers who assume that “natural” means safe.
Unanswered questions about supplement safety for older adults
Several gaps in the evidence remain. Neither COSMOS nor the Physicians’ Health Study II was designed to measure the full range of supplement–drug interactions in participants who were also taking prescription medications. The trials focused on whether multivitamins prevented disease, not on whether they caused harm when combined with other drugs. That means the interaction question, which is arguably the more urgent safety concern for seniors on multiple prescriptions, still lacks the kind of large-scale randomized data that would settle it definitively.
Federal adverse-event reporting systems capture only a fraction of supplement-related incidents. Many interactions go unrecognized because neither the patient nor the prescribing physician connects a new symptom to a supplement. The NCCIH has acknowledged in its overview of how medications and supplements interact that underreporting and limited formal studies leave important blind spots. For older adults, who are more likely to experience side effects from prescription drugs even without additional products in the mix, those blind spots translate into real-world vulnerability.
Another unresolved issue is dose and duration. Many older adults take multivitamins and herbal products not for weeks or months, but for years. Yet much of the safety data comes from shorter-term studies or case reports. Long-term exposure to high doses of certain vitamins, such as vitamin A or vitamin E, has raised concerns in past research, especially for people with underlying conditions. Without trials specifically designed to track long-term outcomes in polypharmacy populations, clinicians are left to extrapolate from incomplete information.
What older adults and clinicians can do now
Despite the uncertainties, the existing evidence supports several practical steps. First, older adults should treat supplements as medications in their own right, not as harmless add-ons. That means bringing every bottle-vitamins, minerals, herbs, and so-called “natural” remedies-to medical and pharmacy visits. A complete list allows clinicians to assess potential overlaps, such as multiple products containing the same ingredient, and to identify combinations that may raise bleeding risk, alter blood pressure, or interfere with drug metabolism.
Second, clinicians can normalize asking about supplement use as part of routine care. Instead of a quick yes-or-no question, a brief, structured checklist can prompt more detailed disclosure. Electronic health records that include a dedicated field for supplements, alongside prescription and over-the-counter medications, would help ensure that this information is visible across care settings. Pharmacists, who often see patients more frequently than physicians, are well positioned to update and reconcile these lists.
Third, health systems can pilot the pharmacist-led reviews that safety experts have proposed. A targeted program might focus on older adults taking anticoagulants, antiarrhythmics, or other drugs with narrow therapeutic windows, where even small changes in blood levels can have serious consequences. By systematically screening for interacting supplements and counseling patients about safer alternatives, such programs could generate the real-world data that large randomized trials currently lack.
Finally, public messaging needs to catch up with the science. Marketing that implies broad disease-prevention benefits from multivitamins can leave older adults with unrealistic expectations and a false sense of security. Clearer communication from health agencies, clinicians, and pharmacists-emphasizing that no pill can substitute for evidence-based prevention strategies like blood pressure control, smoking cessation, and physical activity-would help recalibrate those expectations. For now, the best-supported role for multivitamins in generally healthy seniors is filling occasional dietary gaps, not serving as an insurance policy against cancer or heart disease.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
